for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AVEO Pharmaceuticals, Inc.

AVEO.OQ

Latest Trade

0.92USD

Change

0.01(+0.68%)

Volume

271,398

Today's Range

0.87

 - 

0.96

52 Week Range

0.50

 - 

2.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Aveo Oncology Says 20 Patients Remain Progression Free On Tivozanib Arm

Sept 10 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO ONCOLOGY ANNOUNCES UPDATED OVERALL SURVIVAL HAZARD RATIO OF 0.99 IN PHASE 3 TIVO-3 TRIAL OF TIVOZANIB IN RENAL CELL CARCINOMA.AVEO PHARMACEUTICALS INC - 20 PATIENTS REMAIN PROGRESSION FREE ON TIVOZANIB ARM VERSUS. 2 ON SORAFENIB ARM.AVEO PHARMACEUTICALS - PLANS TO DISCUSS UPDATED OS RESULTS WITH U.S. FDA TO IDENTIFY APPROPRIATE PATH FORWARD FOR TIVOZANIB IN RCC IN Q4.

Aveo Pharmaceuticals Says Matthew Dallas, Chief Financial Officer, Will Resign From Company Effective As Of September 26

Aug 27 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO PHARMACEUTICALS - MATTHEW DALLAS, CHIEF FINANCIAL OFFICER, PROVIDED NOTICE OF HIS INTENTION TO LEAVE COMPANY.AVEO PHARMACEUTICALS INC - DALLAS WILL RESIGN FROM COMPANY EFFECTIVE AS OF SEPTEMBER 26.AVEO PHARMACEUTICALS INC - IN PROCESS OF COMMENCING AN EXTERNAL SEARCH FOR ITS NEXT CHIEF FINANCIAL OFFICER.AVEO PHARMACEUTICALS - MICHAEL BAILEY, CEO, WOULD ASSUME ROLE OF PRINCIPAL FINANCIAL OFFICER UNTIL REPLACEMENT CFO IS APPOINTED.

Aveo Q2 Loss Per Share $0.02

Aug 8 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 REVENUE $700,000 VERSUS $400,000.Q2 LOSS PER SHARE $0.02.Q2 REVENUE ESTIMATE $2.7 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.COMPANY'S CASH RUNWAY IS NOW ANTICIPATED TO EXTEND INTO Q3 OF 2021..

Aveo Pharmaceuticals Posts Q1 Revenue $1.6 Million Versus $1 Million

May 9 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 REVENUE $1.6 MILLION VERSUS $1.0 MILLION.Q1 LOSS PER SHARE $0.06.Q1 REVENUE ESTIMATE $2.2 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-0.05 -- REFINITIV IBES DATA.

Aveo Says CHMP Requires More Mature OS Data Before Drawing Conclusion For Tivo-3 Trial

April 3 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO-AFTER REVIEW OF TIVO-3 TRIAL DATA,CHMP DETERMINED ANALYSES OF VARIOUS FACTORS THAT MAY HAVE IMPACTED PRELIMINARY OS DATA DO NOT FULLY EXPLAIN DISCORDANCE.AVEO PHARMACEUTICALS - CHMP HAS DETERMINED MORE MATURE OS DATA IS REQUIRED PRIOR TO DRAWING CONCLUSION FOR TIVO-3 TRIAL - SEC FILING.AVEO PHARMACEUTICALS - SIMILAR TO FDA, CHMP ACCEPTED PROPOSAL TO CONDUCT ADDITIONAL INTERIM OS ANALYSIS IN AUGUST 2019 FOR TIVO-3 TRIAL.AVEO PHARMACEUTICALS-CHMP PROVIDED THAT REGULATORY ACTION TO BE CONSIDERED IF AUG 2019 INTERIM OS ANALYSIS CONFIRMS NEGATIVE TREND IN OS FOR TIVO-3 TRIAL.

Aveo Reports Full Year 2018 Financial Results And Provides Business Update

March 14 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.AVEO PHARMACEUTICALS INC QTRLY DILUTED LOSS PER SHARE $0.03.AVEO PHARMACEUTICALS INC QTRLY BASIC EARNINGS PER SHARE $0.18.AVEO PHARMACEUTICALS INC QTRLY REVENUES $1,483,000 VERSUS $82,000.

Aveo Says Accepted Recommendation Of FDA To Not Submit Marketing Application For Tivozanib

Jan 31 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO ONCOLOGY ANNOUNCES NDA TIMING UPDATE.AVEO PHARMACEUTICALS- ACCEPTED RECOMMENDATION OF FDA NOT TO SUBMIT NDA FOR TIVOZANIB WITH PRELIMINARY OVERALL SURVIVAL RESULTS FROM PHASE 3 TIVO-3 TRIAL.AVEO PHARMACEUTICALS INC - CO NOW PLANS TO MAKE A NDA FILING DECISION FOLLOWING AVAILABILITY OF MORE MATURE OS RESULTS FOR TIVOZANIB.

Aveo Pharmaceuticals Says Co Entered Agreement With Novartis International Pharmaceutical Regarding Aveo's AV380 Program

Dec 19 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO PHARMACEUTICALS INC - ON DEC. 18, AVEO ENTERED AGREEMENT WITH NOVARTIS INTERNATIONAL PHARMACEUTICAL REGARDING AVEO’S AV380 PROGRAM.AVEO PHARMACEUTICALS INC - ENTERED AV380 AGREEMENT WITH NOVARTIS TO ESTABLISH, CLARIFY TERMS ON WHICH AV380 PROGRAM WILL BE RETURNED TO CO.AVEO PHARMACEUTICALS INC - NOVARTIS WILL MAKE A ONE-TIME PAYMENT TO AVEO OF $2.3 MILLION ON OR BEFORE JANUARY 2, 2019.AVEO PHARMACEUTICALS INC - NOVARTIS WILL PROVIDE THE AV380 DRUG SUPPLY, VALUED AT APPROXIMATELY $4.0 MILLION, TO AVEO AT NO CHARGE.AVEO PHARMACEUTICALS - INTENDS TO USE $2.3 MILLION PAYMENT TO COVER MILESTONE OBLIGATION DUE IN JAN 2019 TO ST. VINCENT’S HOSPITAL SYDNEY - SEC FILING.AVEO PHARMACEUTICALS - NOVARTIS WILL NOT DEVELOP, MANUFACTURE/COMMERCIALIZE ANY ANTI-GDF15 ANTAGONIST ANTIBODY FOR 3 YRS AFTER DATE OF AV380 AGREEMENT.AVEO - DEAL PROVIDES FOR CONTINUED TRANSFER TO CO OF PRECLINICAL, TECHNICAL, MANUFACTURING, OTHER DATA, MATERIALS DEVELOPED BY NOVARTIS.

Aveo Oncology Collaborates With Astrazeneca

Dec 12 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO ONCOLOGY ANNOUNCES IMMUNO-ONCOLOGY CLINICAL COLLABORATION WITH ASTRAZENECA.AVEO PHARMACEUTICALS INC - PHASE 1/2 STUDY WILL EVALUATE COMBINATION OF IMFINZI (DURVALUMAB) AND FOTIVDA (TIVOZANIB) IN FIRST-LINE HCC.AVEO PHARMACEUTICALS INC - AVEO WILL SERVE AS STUDY SPONSOR, WITH STUDY COSTS SHARED EQUALLY BY BOTH PARTIES.AVEO PHARMACEUTICALS INC - CLINICAL DRUG WILL BE SUPPLIED BY EACH RESPECTIVE COMPANY.AVEO PHARMACEUTICALS INC - PHASE 1 PORTION OF STUDY IS EXPECTED TO COMMENCE IN 2019..

Aveo oncology announces extension of debt facility interest only period

Dec 4 (Reuters) - Aveo Pharmaceuticals Inc <AVEO.O>::AVEO ONCOLOGY ANNOUNCES EXTENSION OF DEBT FACILITY INTEREST ONLY PERIOD.AVEO PHARMACEUTICALS - ANNOUNCED 6 MONTH EXTENSION TO INTEREST ONLY PERIOD UNDER EXISTING AMENDED & RESTATED LOAN & SECURITY AGREEMENT WITH HERCULES CAPITAL.AVEO PHARMACEUTICALS - COMPANY WILL BEGIN MAKING PRINCIPAL PAYMENTS ON $20.0 MILLION FACILITY STARTING ON AUGUST 1, 2019.AVEO PHARMACEUTICALS INC - EXTENDS CASH RUNWAY TO FUND PLANNED OPERATIONS INTO Q3 OF 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up